Trial Profile
A Phase I/II, Multi-Center, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Ischemic Stroke
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2019
Price :
$35
*
At a glance
- Drugs Ischaemia-tolerant mesenchymal stem cells (Primary)
- Indications Stroke
- Focus Adverse reactions
- Sponsors Stemedica Cell Technologies
- 30 Oct 2019 According to a Stemedica Cell Technologies media release, data from this trial was presented at the 2019 Congress of Neurological Surgeons (CNS).
- 30 Oct 2019 Results published in the Stemedica Cell Technologies media release
- 30 Oct 2019 According to a Stemedica Cell Technologies media release, Michael Levy is the principal investigator as well as Professor of Neurosurgery at the University of California, San Diego (UCSD).